Background: Congenital cholesteatomas (CC) arise from epithelial remnants around the petrous bone. They enlarge gradually causing progressive destruction and functional damage to the ear and surrounding structures. Because of their insidious course, most patients are misdiagnosed and present late with complications. Methods: This is a retrospective study of 41 cases diagnosed as CC and followed up for 2 years. All patients underwent full audiological evaluation and a radiological study (CT, MRI). Results: The male:female ratio was 2.3: 1, and the mean age was 30.89 years. The mean delay before presentation was 13 months. The commonest presentations in order of frequency were: discharge (60.9%), hearing loss (51.2%), facial paralysis (31.7%) and intracranial complications (31.7%). Forty patients were treated surgically by a variety of approaches depending on the extensions and functional status. The facial nerve was decompressed in 9 cases and cable grafted in 4. Two cases underwent VII-XII anastomosis later on. Conclusion: CC present with a myriad of clinical manifestations and should be suspected in all patients with unexplained otological signs and symptoms. They must be completely excised and the functional status of the ear rehabilitated either immediately or later. Follow-up must be indefinite as they have a high recurrence rate.

Keywords:
Cholesteatoma, Congenital cholesteatoma, Complications, Chronic otitis media
1.
Moffat D, Jones S, Smith W: Petrous temporal bone cholesteatoma: a new classification and long-term surgical outcomes. Skull Base 2008; 18: 107–116.
2.
Profant M, Steno J: Petrous apex cholesteatoma. Acta Otolaryngol 2000; 120: 164–167.
3.
Coker NJ, Jenkins HA, Fisch U: Obliteration of the middle ear and mastoid cleft in subtotal petrosectomy: indications, technique and results. Ann Otol Rhinol Laryngol 1986; 95: 5–11.
4.
Bartels LJ: Facial nerve and medially invasive petrous bone cholesteatomas. Ann Otol Rhinol Laryngol 1991; 100: 308–316.
5.
Sanna M, Zini C, Gamoletti R, et al: Petrous bone cholesteatoma. Skull Base Surg 1993; 3: 201–213.
6.
Magliulo G: Petrous bone cholesteatoma: clinical longitudinal study. Eur Arch Otorhinolaryngol 2007; 264: 115–120.
7.
Omran A, De Donato G, Piccirillo E, Leone O, Sanna M: Petrous bone cholesteatoma: management and outcomes. Laryngoscope 2006; 116: 619–626.
8.
Hidaka H, Ishida E, Kaku K, Nishikawa H, Kobayashi T: Congenital cholesteatoma of mastoid region manifesting as acute mastoiditis: case report and literature review. J Laryngol Otol 2010; 124: 810–815.
9.
Nagato T, Otaka R, Wada T, Kanai N, Harabuchi Y: Congenital cholesteatoma isolated to the mastoid presenting as stricture of the external auditory canal. Int J Pediatr Otorhinolaryngol 2012; 76: 754–756.
10.
Lee JH, Hong SH, Park CH, Jung SH: Congenital cholesteatoma of mastoid origin. J Laryngol Otol 2007; 121:article e20.
11.
Tabook SMS, Tawab HM, Gopal NM: Congenital cholesteatoma localized to the mastoid cavity and presenting as a mastoid abscess. Case Rep Otolaryngol 2015; 2015: 305494.
12.
Kojima H, Tanaka Y, Shiwa M, Sakurai Y, Moriyama H: Congenital cholesteatoma clinical features and surgical results. Am J Otolaryngol 2006; 27: 299–305.
13.
Koltai PJ, Nelson M, Castellon RJ: The natural history of congenital cholesteatoma. Arch Otolaryngol Head Neck Surg 2002; 128: 804–809.
14.
Kim SE, Cho Y, Chu H, Jang JY, Chung WH, Hong SH: Open-type congenital cholesteatoma: differential diagnosis for conductive hearing loss with a normal tympanic membrane. Acta Otolaryngol 2012; 132: 618–623.
15.
Darrouzet V, Duclos JY, Portmann D, Bebear JP: Congenital middle ear cholesteatoma in children: our experience in 34 cases. Otolaryngol Head Neck Surg 2002; 126: 34–40.
16.
Giannuzzi AL, Merkus P, Taibah A, Falcioni M: Congenital mastoid cholesteatoma: case series, definition, surgical key points, and literature review. Ann Otol Rhinol Laryngol 2011; 120: 700–706.
17.
Cazzador D, Favaretto N, Zanoletti E, Martini A: Combined surgical approach to giant cholesteatoma: a case report and literature review. Ann Otol Rhinol Laryngol 2016; 125: 687–693.
18.
Bennett M, Warren F, Jackson GC, Kaylie D: Congenital cholesteatoma: theories, facts, and 53 patients. Otolaryngol Clin North Am 2006; 39: 1081–1094.
19.
Persaud R, Hajioff D, Trinidade A, Khemani S, Bhattacharyya MN, Papadimitriou N, Kalan A, Bhattacharyya AK: Evidence-based review of aetiopathogenic theories of congenital and acquired cholesteatoma. J Laryngol Otol 2007; 121: 1013–1019.
20.
Borsetto D, Faccioli C, Zanoletti E, Martini A: Giant congenital cholesteatoma of the petrous bone: personal experience and literature review. Ann Otolaryngol Rhinol 2015; 2: 1071.
21.
Kazahaya K, Potsic WP: Congenital cholesteatoma. Curr Opin Otolaryngol Head Neck Surg 2004; 12: 398–403.
22.
Magliulo G: Petrous bone cholesteatoma: clinical longitudinal study. Eur Arch Otorhinolaryngol 2007; 264: 115–120.
23.
El-Bitar MA, Choi SS, Emamian SA, Vezina LG: Congenital middle ear cholesteatoma: need for early recognition – role of computed tomography scan. Int J Pediatr Otorhinolaryngol 2003; 67: 231–235.
24.
Sanna M, Pandya Y, Mancini F, Sequino G, Piccirillo E: Petrous bone cholesteatoma: classification, management and review of the literature. Audiol Neurootol 2011; 16: 124–136.
25.
Mierzwinski J, Fishman AJ, Grochowski T, Drewa S, Drela M, Winiarski P, Bielecki I: Cochlear implant and congenital cholesteatoma. J Otolaryngol-Head Neck Surg 2016; 45: 8.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.